Xeris Biopharma Holdings

XERS · NASDAQ

$11.13+$0.18 (+1.64%)TodayMarket closed · Oct 20, 7:34 PM ET

Prev close $10.95

Latest news

Press releaseOct 15, 8:00 AM ETBusiness Wire
Xeris Biopharma Reinforces Leadership in Endocrinology With Data Disclosures Spanning Commercial Portfolio and Pipeline at Multiple Scientific Meetings
NewsOct 6, 6:24 AM ET
Full Transcript: Xeris Biopharma Holdings Q2 2026 Earnings Call
Press releaseOct 2, 5:00 PM ETBusiness Wire
Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
NewsSep 29, 12:37 PM ET
Lundbeck Is Said To Express Interest In Buying Xeris Biopharma, Bloomberg Reports
Press releaseSep 9, 8:30 AM ETBusiness Wire
Xeris Hosts Webinar Detailing Its Comprehensive Development Program for XP-8121, an Investigational, Once-Weekly Subcutaneous Levothyroxine for Hypothyroidism
Press releaseAug 26, 7:30 AM ETBusiness Wire
Xeris Announces Details for XP-8121 Program Overview Webinar
Press releaseAug 6, 7:00 AM ETBusiness Wire
Xeris Biopharma Reports Second Quarter 2026 Financial Results
Press releaseJul 23, 7:30 AM ETBusiness Wire
Xeris Biopharma to Report Second Quarter 2026 Financial Results on August 6, 2026
Press releaseJul 2, 4:05 PM ETBusiness Wire
Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Press releaseJul 2, 4:05 PM ETBusiness Wire
CORRECTING and REPLACING Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Press releaseJun 30, 7:00 AM ETBusiness Wire
Xeris Announces Updates to Its Board of Directors
Press releaseJun 11, 4:39 PM ETBusiness Wire
Xeris Biopharma Announces Notice of Allowance From U.S. Patent and Trademark Office for New Patent Covering KEVEYIS®
Press releaseJun 11, 7:00 AM ETBusiness Wire
Xeris Biopharma Announces Private Exchange of Convertible Notes
NewsMay 7, 7:10 AM ET
Xeris Biopharma Holdings Q1 EPS $0.01 Beats $(0.00) Estimate, Sales $83.127M Beat $79.992M Estimate
Press releaseMay 7, 7:00 AM ETBusiness Wire
Xeris Biopharma Reports First Quarter 2026 Financial Results
Press releaseApr 23, 7:30 AM ETBusiness Wire
Xeris Biopharma to Report First Quarter 2026 Financial Results on May 7, 2026
Press releaseApr 3, 4:15 PM ETBusiness Wire
Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
NewsMar 2, 7:02 AM ET
Xeris Biopharma Holdings Q4 Earnings Assessment
NewsMar 2, 7:01 AM ET
Xeris Biopharma Holdings Q4 EPS $0.06 Beats $0.04 Estimate, Sales $85.807M Beat $82.340M Estimate
Press releaseMar 2, 7:00 AM ETBusiness Wire
Xeris Biopharma Reports Record Performance for Fourth Quarter and Full Year 2025 and Provides Full Year 2026 Guidance
NewsMar 2, 6:11 AM ET
Earnings Scheduled For March 2, 2026
NewsFeb 27, 12:29 PM ETAlex Perry
Why Are Shares Of Xeris Biopharma Falling Friday?
NewsFeb 27, 11:01 AM ET
A Peek at Xeris Biopharma Holdings's Future Earnings
Press releaseFeb 26, 5:55 PM ETBusiness Wire
Xeris Biopharma Subsidiaries File Recorlev® Patent Infringement Lawsuit
Press releaseFeb 17, 7:30 AM ETBusiness Wire
Xeris Biopharma to Report Full Year 2025 Financial Results and Provide Full Year 2026 Guidance on March 2, 2026
Press releaseJan 8, 7:00 AM ETBusiness Wire
Xeris Expects to Deliver Record Fourth Quarter and Full-Year 2025 Total Revenue
Press releaseJan 2, 4:15 PM ETBusiness Wire
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
NewsJan 2, 8:02 AM ETAvi Kapoor
Outlook Therapeutics, Intelligent Bio Solutions And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Press releaseDec 1, 7:00 AM ETBusiness Wire
Xeris Announces Notice of Allowance from U.S. Patent and Trademark Office for XP-8121 Patent Application
Press releaseNov 6, 7:00 AM ETBusiness Wire
Xeris Biopharma Posts Record Financial Results for the Third Quarter 2025
NewsNov 6, 6:12 AM ET
Earnings Scheduled For November 6, 2025
Press releaseOct 23, 7:30 AM ETBusiness Wire
Xeris Biopharma to Report Third Quarter 2025 Financial Results on November 6, 2025
Press releaseOct 3, 4:15 PM ETBusiness Wire
Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Press releaseAug 27, 8:35 AM ETPRNewswire
American Regent® Launches Gvoke VialDx™ (glucagon injection)
Press releaseAug 25, 7:00 AM ETBusiness Wire
Xeris Announces Orange Book Listing of U.S. Patent for Recorlev®
NewsAug 7, 4:33 AM ET
Earnings Scheduled For August 7, 2025
NewsMay 8, 4:33 AM ET
Earnings Scheduled For May 8, 2025
NewsMay 7, 11:02 AM ET
Earnings Outlook For Xeris Biopharma Holdings

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Xeris Biopharma Reinforces Leadership in Endocrinology With Data Disclosures Spanning Commercial Portfolio and Pipeline at Multiple Scientific Meetings

Full Transcript: Xeris Biopharma Holdings Q2 2026 Earnings Call

Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Lundbeck Is Said To Express Interest In Buying Xeris Biopharma, Bloomberg Reports

Xeris Hosts Webinar Detailing Its Comprehensive Development Program for XP-8121, an Investigational, Once-Weekly Subcutaneous Levothyroxine for Hypothyroidism

Xeris Announces Details for XP-8121 Program Overview Webinar

Xeris Biopharma Reports Second Quarter 2026 Financial Results

Xeris Biopharma to Report Second Quarter 2026 Financial Results on August 6, 2026

Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

CORRECTING and REPLACING Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Xeris Announces Updates to Its Board of Directors

Xeris Biopharma Announces Notice of Allowance From U.S. Patent and Trademark Office for New Patent Covering KEVEYIS®

Xeris Biopharma Announces Private Exchange of Convertible Notes

Xeris Biopharma Holdings Q1 EPS $0.01 Beats $(0.00) Estimate, Sales $83.127M Beat $79.992M Estimate

Xeris Biopharma Reports First Quarter 2026 Financial Results

Xeris Biopharma to Report First Quarter 2026 Financial Results on May 7, 2026

Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Xeris Biopharma Holdings Q4 Earnings Assessment

Xeris Biopharma Holdings Q4 EPS $0.06 Beats $0.04 Estimate, Sales $85.807M Beat $82.340M Estimate

Xeris Biopharma Reports Record Performance for Fourth Quarter and Full Year 2025 and Provides Full Year 2026 Guidance

Earnings Scheduled For March 2, 2026

Why Are Shares Of Xeris Biopharma Falling Friday?

A Peek at Xeris Biopharma Holdings's Future Earnings

Xeris Biopharma Subsidiaries File Recorlev® Patent Infringement Lawsuit

Xeris Biopharma to Report Full Year 2025 Financial Results and Provide Full Year 2026 Guidance on March 2, 2026

Xeris Expects to Deliver Record Fourth Quarter and Full-Year 2025 Total Revenue

Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Outlook Therapeutics, Intelligent Bio Solutions And Other Big Stocks Moving Lower In Friday's Pre-Market Session

Xeris Announces Notice of Allowance from U.S. Patent and Trademark Office for XP-8121 Patent Application

Xeris Biopharma Posts Record Financial Results for the Third Quarter 2025

Earnings Scheduled For November 6, 2025

Xeris Biopharma to Report Third Quarter 2025 Financial Results on November 6, 2025

Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

American Regent® Launches Gvoke VialDx™ (glucagon injection)

Xeris Announces Orange Book Listing of U.S. Patent for Recorlev®

Earnings Scheduled For August 7, 2025

Earnings Scheduled For May 8, 2025

Earnings Outlook For Xeris Biopharma Holdings